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Na+/H+ exchanger regulatory factor 1 (NHERF1) is a scaffold protein known to interact with a number
of cancer-related proteins. nherf1 Mutations (K172N and D301V) were recently identiﬁed in breast
cancer cells. To investigate the functional properties of NHERF1, wild-type and cancer-derived nherf1
mutations were stably expressed in SKMES-1 cells respectively. NHERF1-wt overexpression sup-
pressed the cellular malignant phenotypes, including proliferation, migration, and invasion. nherf1
Mutations (K172N and D301V) caused complete or partial loss of NHERF1 functions by affecting the
PTEN/NHERF1/PDGFRb complex formation, inactivating NHERF1 inhibition of PDGF-induced AKT
andERKactivation, andattenuating the tumor-suppressor effects ofNHERF1-wt. These results further
demonstrated the functional consequences of breast cancer-derived nherf1 mutations (K172N and
D301V), and suggested the causal role of NHERF1 in tumor development and progression.
Structured summary of protein interactions:
NHERF1 physically interacts with PDGFRbeta by pull down
NHERF1 physically interacts with PTEN by pull down
PDGFRbeta physically interacts with PTEN and NHERF1 by pull down
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction teins via these domains, and has been implicated not only in regu-Na+/H+ exchanger regulatory factor 1 (NHERF1, also named as
EBP50), was ﬁrst identiﬁed as an essential cofactor for cyclic AMP
inhibition of Na+/H+ exchange in the rabbit renal brush border mem-
brane [1]. It is known to be a scaffold protein highly expressed in the
apical membrane of polarized epithelial cells. NHERF1 consists of
two tandem PDZ domains followed by an ezrin–radixin–moesin
(ERM)-binding region [2,3]. NHERF1 can bind to ion transporters,
G protein-coupled receptors, and cytoskeleton-associated ERM pro-lating diverse biological processes for ion transport and second
messaging cascades, but also in maintaining cell polarity [2,4].
Recently, increasing evidence has demonstrated that NHERF1
can interact with many cancer-related proteins, such as PTEN
[5,6], neuroﬁbromatosis 2 (NF2) [7], spleen tyrosine kinase (SYK)
[8] platelet-derived growth factor receptor (PDGFR) [9], epidermal
growth factor receptor (EGFR) [10] and b-catenin [11,12], suggest-
ing its possible function in carcinogenesis. Indeed, abnormal
expression of NHERF1 has been found in several kinds of tumors,
such as hepatocellular carcinoma, breast cancer, and nerve
schwannoma [11,13,14]. NHERF1 overexpression in breast tumors
is associated with tumor stage, metastatic progression, and poor
prognosis [15,16], implying that NHERF1 is a potential oncopro-
tein. However, contrasting results have recently been reported.
Downregulation of endogenous NHERF1 in breast cancer cells pro-
moted proliferation, tumorigenic ability, and delayed the turnover
of PDGF-induced AKT phosphorylation [17,18]. In our previous
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pressed cell proliferation by promoting apoptosis and inhibiting
ERK activation [19], suggestive of a tumor suppressor role for
NHERF1. These contradictory reports suggest a complicated role
for NHERF1 in breast cancer.
Two pointmutations of nherf1 (K172NandD301V)were recently
identiﬁed in breast cancer cell lines or primary breast tumors [8].
However, there is no direct evidence to support a causal role for
these mutations in cancer development and progression. NHERF1
was reported to form a ternary complex with PDGFR and PTEN in
mouse embryonic ﬁbroblasts. NHERF1 depletion enhanced PDGF-
inducedactivationof the PI3K/AKTpathway, cytoskeletal rearrange-
ments, and chemotactic migration [18]. However, the effects of the
breast cancer-derived nherf1 mutations on the interactions of
NHERF1 with PDGFR and PTEN have not yet been established.
In this context, we investigated the effects of wild-type (wt) and
point mutations of nherf1 (K172N and D301V) on the proliferation,
migration, and invasion of SKMES-1 cells to gain insight into the
NHERF1 function, and to improve our understanding of the role
of NHERF1 in tumor development and progression.
2. Materials and methods
2.1. Expression vectors
NHERF1 cDNA were cloned into pEF6 vector by using pEF6/V5-
His TOPO TA expression kit (Invitrogen, Paisley, Scotland, UK)
according to the manufacturer’s instructions. NHERF1 cDNA of mu-
tants were excised from GST-NHERF1 mutant constructs K172N
and D301V (kindly provided by Dr. Jiale Dai, MD Anderson Cancer
Center, Houston, TX) and were subcloned into pEF6 vector.
PDGFRb-CT encoding the last 43 amino acids of human PDGFRb
was ampliﬁed via PCR and inserted into pGEX-4T-1 for expression
as GST fusion protein.
2.2. Cell lines
Non-small cell lung cancer cell line, SKMES-1, was from the
European Collection for Animal Cell Culture (ECACC, Porton Down,
Salisbury, UK). HeLa and COS-7 cells were from American Type Cul-
ture Collection (ATCC, Manassas, VA). All cells were cultured in
DMEM plus 10% FBS, 1% penicillin and streptomycin (Gibco BRC,
Paisley, Scotland, UK).
2.3. Cell transfection
COS-7 cells and SKMES-1 cells were respectively transfected
with PDGFRb and His-NHERF1 by using Hifection II (Applygen, Bei-
jing, China). COS-7 cells were harvested 36 h after transfection.
SKMES-1 cells were selected with 1.25 lg/ml blasticidin S in cul-
ture medium for further 14 days to generate stable NHERF1-
expressing cell lines. NHERF1 expression was veriﬁed by Western
blotting.
2.4. Knockdown of NHERF1 expression using ribozyme transgenes
Ribozyme transgenes were employed to suppress NHERF1
expression in cells. Brieﬂy, the secondary structure of human
NHERF1 was generated using Zucker’s RNA mFold software. The
ribozyme that speciﬁcally targets NHERF1 was generated using
touchdown PCR with the appropriate primers (sense: 50-
CTGCAGCCGGGGAGTCTGGGTCCACTGACCGCTGATGAGTCCGTGAG-
GA-30; antisense: 50-ACTAGTCCAAGCCAGGCCAGTTCTTTCGTCCTCA
CGGACT-30. The resulting correct inserts were puriﬁed and cloned
into the pEF6/V5-His-TOPO vector, and then transformed into cells.Knockdown of NHERF1 expression was veriﬁed by Western
blotting.
2.5. GST pull-down and Western blotting
GST pull-down assays and Western blotting was performed as
described previously [20]. Anti-PTEN and anti-pS473AKT antibod-
ies were purchased from Cell Signaling Technology (Danvers,
MA), anti-AKT antibody from Sigma (St. Louis, MO), anti-b-actin
from Santa Cruz Biotechnology (Santa Cruz, CA), anti-ERK, anti-p-
ERK and anti-PDGFRb antibodies from Upstate Biotechnology (Lake
Placid, NY). Anti-His antibody was from MBL (Tokyo, Japan). Anti-
NHERF1 antibody was obtained from Cell Signaling Technology
(Danvers, MA).
2.6. Cell proliferation assay
Cells were seeded in a 96-well plate at 2.5  103 cells per well
and were stained with 0.5% crystal violet at indicated time points.
Viable cells were quantiﬁed by measuring absorbance at 540 nm
with an Elx800™ spectrophotometer (BioTek, Winooski, VT).
2.7. Wound-healing assay
The migratory properties of cells were assessed by wound-heal-
ing assay. A variety of cells were seeded at a density of 2  105 -
cells/well into a 24-well plate and allowed to reach conﬂuence.
The layer of cells was then scraped with a ﬁne gauge needle to cre-
ate a wound of approximately 200 lm. The movement of cells to
heal the wound was recorded and analyzed using a time-lapsed vi-
deo system. Migration of the cells was monitored and recorded on
a video for 90 min. Wound closure/cell migration was evaluated
with motion analysis and line morphometry software (Optimus 6).
2.8. Cell invasion assay
Transwell chambers, equipped with a 6.5 mm diameter polycar-
bonate ﬁlter insert (pore size 8 lm) (Becton Dickinson, Labware,
Oxford, UK), were pre-coated with 50 lg/insert of Matrigel (BD
Biosciences, Oxford, UK). Cells were seeded at a density of 3  104 -
cells/insert. 3 days later, the cells that invade through the Matrigel
were ﬁxed, stained, and quantiﬁed as described before [21].
2.9. Statistical analysis
The 2-sample t test was used for normally distributed data. P
Value of less than 0.05 is considered to be statistically signiﬁcant.
3. Results
3.1. NHERF1 overexpression reversed malignant phenotypes of SKMES-
1 cells
Previous studies on the tumor-suppressor functions of NHERF1
were carried out by knockdown of NHERF1 expression in either
normal or high-NHERF1-expressing cancer cell lines [17,18]. How-
ever, suppression of the malignant phenotype by overexpression of
NHERF1 has not yet been extensively studied. It is therefore neces-
sary to determine its biological roles by using a low-NHERF1-
expressing cancer cell model. NHERF1 transcript level was evalu-
ated and compared among different cancer cell lines to screen
the low-NHERF1- expressing cancer cell lines. The lowest level of
NHERF1 transcripts was observed in the SKMES-1 cells (Fig. S1).
NHERF1 was then stably transfected into SKMES-1 cells and its
expression was assessed by Western blotting. The expression level
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compared with parental or vector control cells (Fig. 1A). Major
malignant phenotypes, including cell proliferation, invasion, and
migration, were then evaluated. Compared with parental or vector
control cells, cell proliferation was suppressed by up to 60% in cells
overexpressing NHERF1-wt on day 5 (Fig. 1B). Cell migration and
invasion were also reduced by up to 30% and 25% at 90 min and
72 h, respectively (Fig. 1C–D).
3.2. Breast cancer-derived nherf1 mutations impair tumor-suppressor
function of NHERF1
Two missense mutations of nherf1 (K172N and D301V) were
previously found in a breast tumor and in the SUM149PT breastFig. 1. Breast cancer-derived nherf1mutations (K172N and D301V) abolished the antitum
(E) was stably expressed in SKMES-1 cells, and detected with anti-NHERF1 or anti-His an
and invasion (D) of SKMES-1 cells. nherf1 Mutations (K172N and D301V) inactivated the
panels B–D and F–H, data represent mean values ± standard deviation (SD) of six (B, C
individual experiments. ⁄P < 0.05, ⁄⁄P < 0.01.cancer cell lines, respectively. To further examine if these muta-
tions could inactivate the tumor-suppressor function of NHERF1,
they were introduced into SKMES-1 cells respectively. As demon-
strated by Western blotting, these mutants were expressed at
similar levels to NHERF1-wt (Fig. 1E). We then explored their ef-
fects on the malignant phenotype of cancer cells, such as prolifer-
ation, migration and invasion. As shown in Fig. 1F, each of the
nherf1 mutations signiﬁcantly inactivated the cell proliferation
suppressed by NHERF1-wt, to a similar level that shown in vehicle
control cells. In wound healing assay, both of the nherf1 mutations
abolished the inhibition of NHERF1-wt-mediated cell migration,
since there were no signiﬁcant differences in migration rates be-
tween control and both of the two mutants-expressing cells
(K172N and D301V) (Fig. 1G), which is consistent with the resultsor effects of NHERF1 in SKMES-1 cells. Exogenous NHERF1 wild type (A) or mutants
tibodies. NHERF1-wt overexpression suppressed cell proliferation (B), migration (C),
cell proliferation (F), migration (G) and invasion (H) suppressed by NHERF1-wt. In
, F, G) or triplicate (D, H) samples. The results shown are representative of three
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Similarly, cell invasion rates of both mutants had no statistically
difference compared with vehicle control cells (Fig. 1H). These re-
sults indicated that NHERF1-wt acted as a tumor suppressor in
SKMES-1 cells, and the breast cancer-derived nherf1 mutations
(K172N and D301V) abolished or reduced its function of tumor-
suppressor effects.
3.3. NHERF1 facilitates the formation of PTEN/NHERF1/PDGFRb
complex
It has been proven that NHERF1 inhibits PDGF signaling in
breast cancer cells, and NHERF1 has been reported to interact
with PTEN and PDGFRb respectively [17]. However, there is no di-
rect evidence that NHERF1 can bridge the PTEN/NHERF1/PDGFRb
complex. To conﬁrm the role of NHERF1 in the formation of the
PTEN/NHERF1/PDGFRb complex, GST-PDGFRb-CT fusion protein
beads were incubated with the protein extracts from COS-7 cells,
and endogenous PTEN were then detected by Western blotting.
As shown in Fig. 2A, NHERF1 overexpression robustly enhanced
the amount of PTEN in the pull-down complexes. Accordingly,Fig. 2. nherf1 Mutations (K172N and D301V) reduced the afﬁnity of NHERF1 with PTEN
complex formation in COS-7 cells. GST-PDGFRb-CT beads were incubated with lysates of C
were then subjected to NHERF1 and PTEN immunoblotting respectively. (B) Knocking d
COS-7 cells were transfected with vector control or NHERF1 ribozyme and then harveste
the cell lysates. The bound proteins were subjected to PTEN and NHERF1 immunoblottin
GST-NHERF1 beads were incubated with COS-7 cell lysates, and then the pull-down com
D301V) affected NHERF1 interaction with PDGFRb by GST pull-down assay. GST-NHERF
bound proteins were subjected to PDGFRb immunoblotting. In A and B, the cell lysates we
to visualize the same amount of input fusion protein. The signals were quantiﬁed by d
experiments.knockdown of NHERF1 expression decreased the amount of PTEN
in the pull-down complexes (Fig. 2B). These data indicated that
NHERF1 could facilitate the PTEN/NHERF1/PDGFRb complex
formation.
3.4. nherf1 Mutations alter its interaction with PTEN and PDGFRb
To further investigate if nherf1 mutations could affect the for-
mation of PTEN/NHERF1/PDGFRb complex, various GST-NHERF1
fusion protein beads were incubated with protein extracts from
COS-7 cells, and PTEN were then detected in the pull-down com-
plex. GST-NHERF1-wt associated robustly with endogenous PTEN
protein, whereas GST alone did not. Although both NHERF1-
K172N and NHERF1-D301V were able to bind to PTEN, their afﬁn-
ities with PTEN were reduced by almost 20%, compared with that
of NHERF1-wt (Fig. 2C). Furthermore, the effect of the mutations
on the NHERF1-wt/PDGFRb interaction were also analyzed in
COS-7 cells transfected with PDGFRb. GST-NHERF1-wt robustly
associated with exogenous PDGFRb protein, and this interaction
was unaffected by NHERF1-K172N mutation; however, NHERF1-
D301V promoted up to a 2-fold increase in NHERF1-PDGFRb inter-or PDGFRb. (A) Overexpressing NHERF1-wt enhanced the PTEN/NHERF1/PDGFRb
OS-7 cells transfected with control vector or pEF-NHERF1-wt. Pull-down complexes
own NHERF1 expression attenuated the PTEN/NHERF1/PDGFRb complex formation.
d in lysis buffer 48 h post-transfection. GST-PDGFRb-CT beads were incubated with
g. (C) nherf1 Mutations (K172N and D301V) altered NHERF1 interaction with PTEN.
plexes were subjected to PTEN immunoblotting. (D) nherf1 Mutations (K172N and
1 beads were incubated with lysates of COS-7 cells transfected with PDGFRb. The
re normalized by the same amount of PTEN. In A–D, the Coomassie-blue stained gel
ensitometry analysis. The results represent mean values ± SD of three independent
S. Cheng et al. / FEBS Letters 587 (2013) 3289–3295 3293action (Fig. 2D). These results suggested that NHERF1-K172N and
NHERF1-D301V could affect the formation of PTEN/NHERF1/
PDGFRb complex.
3.5. nherf1 Mutations inactivate NHERF1 inhibition of AKT and ERK
activation induced by PDGF
The PTEN/NHERF1/PDGFRb complex has been reported to be in-
volved in the regulation of AKT and ERK signaling pathways, which
in turn control important biological functions such as cell prolifer-
ation and migration [5,17,18]. Since nherf1 mutations affected the
PTEN/NHERF1/PDGFRb complex formation, it was reasonable to as-
sume that these mutations could also affect PI3K/AKT or ERK sig-
naling. To test this hypothesis, we detected phosphorylation of
AKT and ERK in SKMES-1 cells transfected with various NHERF1
constructs. Both AKT (Fig. 3A) and ERK (Fig. 3B) were dramatically
phosphorylated in either SKMES-1 parental or vector control cells
following 15-min stimulation with PDGF. NHERF1-wt overexpres-
sion signiﬁcantly inhibited both AKT and ERK activation. However,
the NHERF1 mutations, especially D301V, totally abolished the
NHERF1-wt inhibition of AKT and ERK activation (Fig. 3), Mean-
while the base levels of AKT and ERK activation have no detectable
difference in cells transfected with a variety of NHERF1 constructs
(Fig. S2). Taken together, these data suggested that cancer-derived
nherf1 mutations (K172N and D301V) abolished the inhibition of
PI3K/AKT and/or ERK signaling pathways activation induced by
PDGF.
4. Discussion
Previous reports have been suggested that NHERF1 plays a
tumor suppressor role in breast cancer cell lines. NHERF1 inhib-
ited canonical Wnt signaling and Wnt-dependent cell prolifera-
tion in MCF7 and MDA MB-231 cells [22]; By interaction with
PTEN, NHERF1 counterbalanced PI3K/Akt oncogenic signaling
and enhanced cells respond to PDGFR inhibitor in breast cancer
cell lines [9,18,23]; NHERF1 knockdown accelerated cell cycle
progression accompanied by increased expression of cyclin E
and elevated Rb phosphorylation level [17]. Furthermore, the
mammary glands of NHERF1-knockout mice exhibit increased
mammary duct density accompanied by increased proliferationFig. 3. nherf1 Mutations (K172N and D301V) cause loss-of-function of NHERF1 inhibition
various of NHERF1 mutants were serum starved overnight, and then stimulated with or w
p-ERK antibody (B) (upper panels). Membranes were stripped and reprobed with anti-AK
densitometry analysis (lower panels). Data is given as fold of stimulated parental cells. T
relative to the cells transfected with NHERF1-wt.and b-catenin activity [22]. The present study showed that over-
expression of NHERF1 reduced cell proliferation, motility, and
invasion of low-NHERF1-expressing SKMES-1 cells, and knock-
down of NHERF1 enhanced the migratory and invasive ability of
MCF-7 cells (Fig. S3). Two point mutations of nherf1 (K172N
and D301V) has recently been identiﬁed in breast cancer cells
and breast tumor [8], but it has not yet been characterized if
these mutations cause NHERF1 loss-of-function. The current
studies showed that the K172N and D301V mutants signiﬁcantly
inactivated the NHERF1 suppression of SKMES-1 cells prolifera-
tion, migration, and invasion. The results of both gain-of-function
and loss-of-function studies indicated that NHERF1 acted as a tu-
mor suppressor in tumor cells.
In clinical perspectives, NHERF1 overexpression was observed
in breast cancer tissues, which is associated with increasing tumor
grade, aggressive clinical behavior, and poor prognosis [24–26].
This was contradictory with NHERF1 to be a cancer suppressor.
However, it has been proven that compensatory expression mech-
anisms exist for many anti-oncogenes [27–29]. The p73, as the ﬁrst
discovered anti-oncogene of p53 family member, is a stress-re-
sponse gene and a downstream effector in the p53 pathway [27].
The p73 protein is expressed at very low levels in normal tissues
and differentially expressed in a number of tumors [28,29].
P16INK4A is recognized as a tumor suppressor mainly because of
the prevalence of genetic inactivation of the p16INK4A gene in virtu-
ally all types of human cancers. However, it has also been shown
that an elevated level of expression (upregulation) of P16INK4A is in-
volved in cellular senescence, and cancer progression [30,31]. Thus,
upregulation of NHERF1 expression during breast carcinogenesis
might also involve compensatory mechanism.
NHERF1, as a signaling adaptor, can regulate multiple cellular
processes via interaction with its different binding partners.
NHERF1 mutations may alter the binding afﬁnity of NHERF1 to
some of its signaling partners, and lead to the loss of its anticancer
functions. Here, we found that NHERF1-K172N and NHERF1-
D301V mutants attenuated its interaction with PTEN;
NHERF1-D301V mutant increased its interaction with PDGFRb.
Furthermore, we previously identiﬁed Ser302 as a phosphorylation
site by cdc2, and this phosphorylation has been shown to regulate
NHERF1 homodimerization [32]. D301V mutation is adjunct to
Ser302 residue. Thus, it will be interesting to investigate ifof AKT and ERK activation induced by PDGF. SKMES-1 cells stably transfected with
ithout PDGF for 15 min. Immunoblot was detected with anti-pS473AKT (A) or anti-
T (A) or anti-ERK (B) respectively in middle panels. The signals were quantiﬁed by
he results represent mean values ± SD of three independent experiments. ⁄P < 0.05
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and further modify NHERF1 intramolecular interaction.
Except K172N and D301V, other point mutations in nherf1
including R180W have also been identiﬁed in breast cancer cells
by Dai‘s team [8] and our unpublished data. R180W mutation
also abolish the tumor-suppressor effects of NHERF1, even
though the R180W mutation has less effect of NHERF1 interac-
tion with PTEN or PDGFRb (data not shown), and it may inﬂuence
its interaction with other tumor suppressors such as SYK and
Merlin [8]. Different point mutation may result in the different
changes in spatial structure which could lead to the different bio-
logic activities in cells. These ﬁndings further support the tumor-
suppressor function of NHERF1 in tumor cells, and suggest that
these NHERF1 mutations may play a causal role in tumor devel-
opment and progression.
It was reported that knockdown of NHERF1 expression leads
to defective PTEN recruitment to PDGFR, suggesting NHERF1 is
required for the PDGFRb/PTEN complex assembly [5]. However,
there is no direct evidence that NHERF1 bridges the PTEN/
NHERF1/PDGFRb complex. Here, to conﬁrm the role of NHERF1
in the formation of the PTEN/NHERF1/PDGFRb complex, we con-
ducted a pull-down experiment (Fig. 2A and B) using GST-
PDGFRb-CT to pull down the COS-7 lysates with both NHERF1
overexpression (Fig. 2A) or knockdown (Fig. 2B). Either overex-
prssion or knockdown of NHERF1 signiﬁcantly inﬂuenced the
PTEN/PDGFRb interaction, which directly demonstrated that
NHERF1 bridged the formation of PTEN/NHERF1/PDGFRb com-
plex. Disruption of this complex was reported to lead to an in-
crease of PDGF-induced AKT signaling and cell migration [18].
In this study, we showed that nherf1 K172N and D301V muta-
tions markedly inactivated NHERF1-suppressed activation of
AKT and ERK upon PDGF stimulation. Hence, loss of the sup-
pression of ERK and AKT activities in the cells carrying nherf1
mutations might explain their increased cell proliferative
phenotype.
The nherf1 mutations were initially identiﬁed from breast can-
cer cells and tissues. However, NHERF1 was highly expressed in
all of the breast cancer cell lines which we screened, and the only
cell line suitable for this study was SKMES-1, a lung cancer cell line
(Fig. S1). The data obtained here therefore have implications on
breast cancer as well as on lung cancer. Our preclinical study
showed that NHERF1 expression deregualted in human lung can-
cer, and associated with lung cancer metastasis. Also, NHERF1
expression levels were negatively correlated with aggressive stage
of lung cancer (our unpublished data). It has also been shown that
NHERF1 plays an important role in the respiratory condition in cys-
tic ﬁbrosis [33,34]. In human lung cancer, however, the candidate
binding partners have been demonstrated to be aberrant and are
linked to disease progression. Targeting of these partners proteins
have been demonstrated to be beneﬁcial to the patients. For exam-
ples, PDGFR inhibitors showed potential beneﬁt in reducing
growth of lung tumor [35,36]. The same have been reported for
Akt, PI3K and EGFR [37,38].
Overall, our study demonstrated that NHERF1-wt overexpres-
sion reversed the malignant phenotypes of SKMES-1 cells, includ-
ing cell proliferation, migration, and invasion. Breast cancer-
derived nherf1 mutations (K172N and D301V) affected the forma-
tion of PTEN/NHERF1/PDGFRb complex, inactivated the NHERF1
inhibition of PDGF-induced AKT and ERK activation, and resulted
in complete or partial loss of the tumor-suppressor effects of
NHERF1-wt. These results support a role for nherf1 mutation in tu-
mor development and progression, and provide an evidence of the
functional consequences and signaling properties of breast cancer-
derived nherf1 mutations, thus gain more insight into the patho-
genesis of breast cancer and lung cancer.Acknowledgements
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